Trial Profile
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms MARINER
- Sponsors Janssen Research & Development; Janssen-Cilag
- 07 Apr 2022 Results of a pooled analysis (MAGELLAN and MARINER trials data) assessed that the patients with major bleeding but not those with non-major clinically relevant bleeding, would be at an increased risk of all-cause mortality published in the Circulation
- 27 Jul 2021 Results of subgroup analysis assessing rates of efficacy and safety outcomes for rivaroxaban versus placebo in patients with 75 years of age or older with those in patients less than 75 years of age published in the Journal of Thrombosis and Haemostasis
- 30 Jun 2020 Results published in the Journal of the American College of Cardiology